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Background: Leading theories about the pathogenesis of fibromyalgia focus on central nervous dysregulation or
sensitization, which can cause altered perception. There is growing evidence that fibromyalgia involves altered
perception not only of pain, but also other sensory stimuli. On this basis, we investigated whether individuals with
fibromyalgia are more likely to report subjective loss of hearing, adjusted for audiometrically measured loss of
hearing, compared to persons without any musculoskeletal pain disorders. In addition, we studied persons with
other musculoskeletal pain than fibromyalgia and persons who did not have any musculoskeletal pain.
Methods: The study includes 44 494 persons from the second health survey in Nord-Trøndelag (HUNT2) who
had undergone audiometry and answered a comprehensive questionnaire that mapped fibromyalgia,
musculoskeletal pain at various sites and subjective hearing loss. Respondents with other musculoskeletal pain
problems than fibromyalgia were divided into two groups with respectively localized and widespread
musculoskeletal pain. Data were analyzed with logistic regression models adjusting for age, education, anxiety,
depression and hearing thresholds.
Results: In adjusted analysis, individuals with fibromyalgia had increased likelihood to report subjective hearing
loss, compared to persons without fibromyalgia or other musculoskeletal pain (OR 4.578, 95% CI 3.622–5.787 and
OR 4.523, 95% CI 3.077–6.647 in women and men). Furthermore, people with local and widespread musculoskeletal
pain not diagnosed with fibromyalgia, also had increased likelihood to report subjective hearing loss, compared to
people with no musculoskeletal pain. This relationship was greater for widespread pain than for localized pain (OR 1.
915, 95% CI 1.627–2.255, and 1.796, 95% CI 1.590–2.029, in women and men with local musculoskeletal pain and OR 3.
073, 95% CI 2.668-3.539, OR 3.618, 95% CI 3.225–4.058, in women and men with widespread pain, respectively).
Conclusions: Our findings are consistent with the hypothesis that fibromyalgia is related to a general dysregulation of
the central nervous system. The same might also be the case for other local and, in particular, other widespread,
musculoskeletal pain.
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Prolonged pain from the musculoskeletal system and
other symptoms currently associated with the diagno-
sis fibromyalgia have been described since ancient
times [1, 2]. In the 1500s such symptoms was termed
“rheumatism” [3] and in the 1700s “muscular rheuma-
tism” [3]. From the early 1900s the term “psychogenic
rheumatism” was presented, although it was assumed
to be caused by muscular inflammation and preferen-
tially named “fibrositis” [4–6]. Eventually, in 1976, the
term fibromyalgia was coined [7], as the symptoms
were no longer considered to have an inflammatory
cause, i.e. the past prevailing paradigm since Gowers
in 1904 [3, 8]. The etiology and pathogenesis is since
then often characterized as medically unexplained [9].
However, fibromyalgia may be considered as a
“discrete diagnosis or as a constellation of symptoms
characterized by central nervous system pain amplifi-
cation with concomitant fatigue, memory problems,
and sleep and mood disturbances”[10]. The estimated
prevalence of fibromyalgia in the general population
varies globally between approximately 2 and 11%, de-
pending on the population and study design [10, 11].
The prevalence is higher in women than men (9:1),
and increasing with age [12]. The diagnosis has until
recently been determined by clinical examination ac-
cording to the ACR 1990 criteria, in which the pa-
tient must have pain in all of the body’s four
quadrants plus axial pain, and at least 11/18 prede-
fined tender points, triggered by a pressure of a max-
imum of 4 kg/cm2 [13]. In addition to being a
chronic, widespread musculoskeletal pain condition
without a well-defined cause, fibromyalgia is often ac-
companied by non-specific symptoms and comorbidi-
ties [14–16]. These include symptoms such as fatigue,
memory and concentration problems [17], sleep dis-
turbances, stomach ache, depressive symptoms and
headache [10, 18, 19], and disorders like irritable
bowel syndrome (IBS), chronic fatigue syndrome
(CFS/ME), interstitial cystitis (IC) and temporoman-
dibular disorder (TMD) [8].
Due to the high prevalence of symptoms and co-
morbidities associated with fibromyalgia, researchers
in various milieus have started to view fibromyalgia
and related conditions as potentially explained by the
same mechanisms [20]. The prevailing view is that
they represent a similar, altered central neural pro-
cessing of perceptive stimuli, rather than organ-
specific pathology. One suggested term to cover such
a neural dysregulation condition is “centralized
sensitization syndrome” (CSS) [21, 22]. Other research
groups have launched concepts and theories, which
are theoretically in good coherence with the notion of
central sensitization. These include sustained arousal[23], the Cognitive Activation Theory of Stress
(CATS) [24] and allostatic overload [25]. Currently,
these concepts exist more or less in parallel, and no
consensus exists about the mechanisms [26, 27].
However, the diagnostic criteria for fibromyalgia have
since 2010 been adapted to accommodate the fre-
quent occurrence of associated symptoms and comor-
bidities [18]. The diagnosis can now be established by
therapist interviews and self-reports by summing the
pain localizations (0–19) in a “widespread pain index”
(WPI) plus adding a 0–12 ranged “symptom severity”
score (SSS) considering the comorbid symptoms men-
tioned above. This completes the ACR 2010 fibro-
myalgia criteria and the later 2011 “Fibromyalgia
survey criteria” by a sum score of maximum 31
points where the fibromyalgia diagnosis is defined by
a 12 point cut-off score [18, 19].
Recently, researchers have taken interest in how pa-
tients with fibromyalgia experience hearing. One
study has found increased incidence of reported sub-
jective hearing loss among persons with fibromyalgia,
compared to individuals with inflammatory rheumatic
disorders [28]. Fibromyalgia has also been associated
with hypersensitivity to noise [29]. These findings are
interesting in light of the theories concerning central
sensitization, and are compatible with studies of cog-
nitive dysfunction and memory problems in fibro-
myalgia and chronic widespread pain [17]. Another
study has found poor correlations between subjective
and objective hearing loss in patients with three or
more medical unexplained symptoms, but that study
did not include fibromyalgia per se [30]. It is thereby
still unclear whether persons with fibromyalgia are
more likely to report hearing loss than others. Ac-
cording to the theory of sustained arousal, one might
hypothesize that if persons with fibromyalgia can be
shown to experience auditory disturbances in addition
to the previously documented problems with cognitive
function and memory [17], similar auditory distur-
bances might also be found in persons with wide-
spread muscular pain.
Based on The Nord-Trøndelag Health Study part 2
(HUNT2) and Nord-Trøndelag Hearing Loss study
(NTHLS), the aim of the present study was to explore if
people who report fibromyalgia or other musculoskeletal
pain are more likely to have subjective hearing loss,
compared to controls without such problems. More spe-
cifically, our research question is:
Are persons with fibromyalgia or other musculoskel-
etal pain, widespread or localized, more likely to report
subjective hearing loss than persons without fibromyal-
gia or other pain, when adjusting for measured hearing
thresholds, age, gender and education, as well as depres-
sion and anxiety?
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Study design and participants
Data from HUNT 2 (1995–7) and the NTHLS were used
in a retrospective cross-sectional study. HUNT2 and
NTHLS are questionnaire-based, but hearing loss was
assessed by audiologists who used mobile research units
to measure audiometry.
In total, 66 140 adults, age ranging from 20 to
101 years participated in HUNT2. Median age was 48,
and mean age 50.2 years [31]. Hearing tests were avail-
able for 50 465 participants. Persons with missing data
on fibromyalgia, musculoskeletal pain and subjective
hearing loss were excluded from the present study
(Fig. 1). All participants in HUNT 2 and NTHLS pro-




Fibromyalgia was assessed with the question: “Has a
physician ever said that you have had fibromyalgia
(fibrositis/chronic pain syndrome)?” (HUNT 2 Q1)
[32], with response alternatives “yes” or “no”. An af-
firmative answer to this question classified respon-
dents as having fibromyalgia. It is not known to what
extent physicians used the tender-point criteria when
establishing the diagnosis [13].
Other musculoskeletal pain
Other musculoskeletal symptoms than fibromyalgia
were evaluated by self-report questions from the
HUNT2 Q1 questionnaire [32]. Similar questions have
shown good sensitivity and reproducibility in earlier
studies [33–35]. The initial question was: “Have you
during the past year suffered from pain and/or stiffness
in muscles and limbs that have lasted for at least threeFig. 1 Inclusion formconsecutive months? If so, where did you have these
ailments?” Subsequently the participant could select be-
tween 10 different localizations [36]. Affirmative an-
swers to one or more of the questions concerning
musculoskeletal pain or stiffness, and not “yes” to the
fibromyalgia question, were categorized as “having
other musculoskeletal pain than fibromyalgia”.
Widespread or localized pain
Persons with muscular and/or skeletal problems in three
or more localizations were categorized as having “wide-
spread musculoskeletal pain” [37]. Those who had one
to two localizations for musculoskeletal pain were cate-
gorized as having “localized musculoskeletal pain”.
Subjective hearing loss
Subjective hearing loss (dependent variable) was assessed
by the following questions and follow-up questions [32]:
“Do you have any long-term illness, injury or suffering
of physical or psychological nature that impairs your
functioning in your daily life?”. Then, if yes, “Impaired
hearing?” and “How much would you say that your func-
tions are impaired?” with grading options 0–3 (0 = not
impaired, 1 = slightly impaired, 2 =mediocrely impaired
and 3 = seriously impaired). Options 1–3 were inter-
preted as subjective loss of hearing.
Audiometry
Audiometry measured the hearing threshold for air con-
duction. It was performed by trained personnel under
good conditions [31, 38], and the method test-retest reli-
ability is high [39]. The audiometry was performed auto-
matically with earmuffs connected to a PC. In cases
where the participant was not able to conduct the test
automatically, it was performed manually. Hearing
thresholds were measured by increasing sound levels
until there was a response from the person, and then the
sound level was lowered by 10 dB and then increased by
5 dB, until a response was given once more [39]. The
frequencies 500, 1000, 2000 and 4000 Hz for both ears
form the basis of a mean hearing threshold in this study.
Hearing loss is defined by the World Health
Organization (WHO) as a mean hearing threshold of
26 dB or higher [40]. Mild hearing loss is mean hearing
threshold of both ears between 26.0 dB and 40.9, moder-
ate hearing loss is between 41.0 and 60.9 dB, and severe
hearing loss is defined by mean hearing threshold of
61.0 dB or above [41].
Depression and anxiety symptoms
Symptoms of depression and anxiety were assessed with
the “Hospital Anxiety and Depression Scale” (HADS), a
self-report form with seven questions for depressive
symptoms (HADS-D) and seven questions for anxiety








FM vs Ref MS vs Ref
Total N (%) 1 483 (100) 18 808 (100) 24 203 (100)
Women N (%) 1 275 (85.97) 9 948 (52.89) 11 860 (49.00) 0.000 0.000
Age Mean (SD) 52.43 (12.02) 51.64 (15.56) 45.99 (16.77) 0.000 0.000
Single N (%) 453 (30.55) 6 340 (33.71) 10 319 (42.63) 0.000 0.000
Education 0.000 0.000
Primary school N (%) 716 (48.28) 7 042 (37.44) 6 647 (27.46)
High school N (%) 552 (37.22) 7 936 (42.19) 11 091 (45.82)
Higher N (%) 215 (14.50) 3 830 (20.36) 6 465 (26.71)
Audiometry (MTH) Mean (SD) 16.82 (13.19) 17.65 (14.80) 14.29 (13.86) 0.000 0.000
HADS-Ab Mean (SD) 6.38 (4.16) 4.63 (3.43) 3.57 (2.86) 0.000 0.000
HADS-Db Mean (SD) 5.07 (3.65) 3.83 (3.15) 2.81 (2.67) 0.000 0.000
Reference = Ref = participants without fibromyalgia and musculoskeletal pain disorders
MTH =mean threshold of hearing based on pure tone audiometry at frequencies 0.5, 1, 2 and 4 kHz on both ears
HADS-A = self-reported questionnaire for symptoms of anxiety
HADS-D = self-reported questionnaire for symptoms of depression
aDescriptive comparison of categorical variables performed with chi-square and continuous variables with two-sided t-test
bMissing data from several participants on this variable. Applicable for FM, MSD and Ref
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points of each sub-scale. A score of ≥8 on each subscale
indicates clinically relevant symptoms consistent with
depression (HADS-D) or anxiety (HADS-A) [42]. The
HADS has been validated in Norway and found suitable
for screening purposes [43].Demographic and socioeconomic status
Demographic variables were gender and age (whole
years) and assessment of socioeconomic status includedTable 2 Local vs widespread musculoskeletal pain disorders withou
Local musculoskeletal pain (LMS) Wides
Total N (%) 8 749 (100) 10 05
Women N (%) 4 158 (47.52) 5 790
Age Mean (SD) 50.65 (16.21) 52.50
Single N (%) 3 067 (35.06) 3 273
Education
Primary school N (%) 2 937 (33.57) 4 105
High school N (%) 3 805 (43.49) 4 131
Higher N (%) 2 007 (22.94) 1 823
Audiometry (MTH) Mean (SD) 17.26 (14.81) 18.00
HADS-Ab Mean (SD) 4.13 (3.11) 5.07 (
HADS-Db Mean (SD) 3.48 (2.97) 4.14 (
MTH =mean threshold of hearing based on pure tone audiometry at frequencies 0.
HADS-A = self-reported questionnaire for symptoms of anxiety
HADS-D = self-reported questionnaire for symptoms of depression
aDescriptive comparison of categorical variables performed with chi-square and con
bMissing data from several participants on this variable. Applicable for FM, MSD andlevel of education (highest completed - from primary
school to university) [31].
Statistical analysis
Data was analyzed using SPSS version 22. Group differ-
ences of the participants were described by chi-square
test for categorical variables and two-sided t-test for
continuous variables.
Unadjusted and adjusted logistic regression analyses
(the Enter method, i.e. including all relevant variables
simultaneously) were used to assess the main outcomet fibromyalgia












5, 1, 2 and 4 kHz on both ears
tinuous variables with two-sided t-test
Ref
Table 3 OR (95 % CI) for subjective hearing loss by fibromyalgia, socioeconomic conditions, measured hearing loss, depression and
anxiety in women and mena
Subjective hearing loss Unadjusted Adjusted for age,
education and hearing
loss (model 1)




N (%) N (%) OR (95% CI) OR (95% CI) OR (95% CI)
WOMEN (13 135) 1 085 (8.26) 12 050 (91.74)
Fibromyalgia
No 805 (6.79) 11 055 (93.21) 1.000 ref 1.000 ref 1.000 ref
Yes 280 (21.96) 995 (78.04) 3.865 (3.324–4.493) 5.182 (4.278–6.277) 4.578 (3.622–5.787)
Age
20–35 89 (2.09) 4 162 (97.91) 1.000 ref 1.000 ref 1.000 ref
36–49 135 (3.36) 3 881 (96.64) 1.627 (1.240–2.133) 1.069 (0.801–1.426) 0.974 (0.713–1.329)
50–64 279 (10.24) 2 445 (89.76) 5.336 (4.182–6.809) 2.072 (1.565–2.743) 1.952 (1.437–2.651)
65+ 582 (27.15) 1 562 (72.85) 17.424 (13.837–21.942) 2.354 (1.747–3.172) 2.071 (1.474–2.909)
Education
Primary school 659 (15.45) 3 606 (84.55) 1.000 ref 1.000 ref 1.000 ref
High school 247 (4.49) 5 255 (95.51) 0.257 (0.221–0.299) 0.807 (0.665–0.980) 0.736 (0.588–0.921)
Higher 179 (5.15) 3 189 (94.69) 0.307 (0.259–0.365) 0.811 (0.658–1.000) 0.799 (0.618–1.032)
WHO hearing impairment
None (<26 dB) 377 (3.31) 11 007 (96.69) 1.000 ref 1.000 ref 1.000 ref
Mild (26–40 dB) 325 (28.33) 822 (71.67) 11.544 (9.793–13.606) 7.859 (6.404–9.644) 8.082 (6.340–10.302)
Moderate (41–60 dB) 291 (59.75) 196 (40.25) 43.348 (35.201–53.380) 31.533 (24.444–40.678) 35.904 (26.424–48.786)
Severe (>60 dB) 92 (78.63) 25 (21.37) 107.442 (68.247–169.148) 81.067 (50.190–130.939) 90.053 (49.378–164.234)
HADS–A ≥8b
No 606 (6.11) 9 312 (93.89) 1.000 ref 1.000 ref
Yes 178 (11.83) 1 327 (88.17) 2.061 (1.727–2.460) 1.732 (1.353–2.217)
HADS-D ≥8b
No 786 (6.91) 10 590 (93.09) 1.000 ref 1.000 ref
Yes 155 (17.44) 734 (82.56) 2.845 (2.358–3.433) 1.131 (0.849–1.508)
Nagelkerke R2 0.389 0.375
−2 Log likelihood 5 056.265 3 744.466
MEN (12 551) 1 404 (11.19) 11 147 (88.81)
Fibromyalgia
No 1 335 (10.82) 11 008 (89.18) 1.000 ref 1.000 ref 1.000 ref
Yes 69 (33.17) 139 (66.83) 4.093 (3.050–5.493) 4.368 (3.082–6.189) 4.523 (3.077–6.647)
Age
20–35 150 (3.93) 3 666 (96.07) 1.000 ref 1.000 ref 1.000 ref
36–49 173 (4.54) 3 638 (95.46) 1.162 (0.930–1.453) 1.007 (0.800–1.268) 0.966 (0.757–1.233)
50–64 332 (12.40) 2 346 (87.60) 3.459 (2.833–4.223) 1.692 (1.351–2.119) 1.609 (1.262–2.050)
65+ 749 (33.35) 1 497 (66.65) 12.228 (10.159–14.718) 2.116 (1.661–2.695) 1.837 (1.404–2.403)
Education
Primary school 611 (19.72) 2 487 (80.28) 1.000 ref 1.000 ref 1.000 ref
High school 505 (8.22) 5 636 (91.78) 0.365 (0.321–0.414) 0.914 (0.783–1.066) 0.886 (0.757–1.233)
Higher 288 (8.70) 3 024 (91.30) 0.388 (0.334–0.450) 0.824 (0.691–0.981) 0.765 (0.622–0.940)
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Table 3 OR (95 % CI) for subjective hearing loss by fibromyalgia, socioeconomic conditions, measured hearing loss, depression and
anxiety in women and mena (Continued)
WHO hearing impairment
None (<26 dB) 438 (4.36) 9 618 (95.64) 1.000 ref 1.000 ref 1.000 ref
Mild (26–40 dB) 439 (28.16) 1 120 (71.84) 8.607 (7.437–9.961) 5.625 (4.713–6.715) 6.157 (5.054–7.500)
Moderate (41–60 dB) 410 (53.39) 358 (46.61) 25.148 (21.194–29.841) 15.120 (12.203–18.734) 17.012 (13.214–21.902)
Severe (>60 dB) 117 (69.64) 51 (30.36) 50.376 (35.766–70.955) 31.310 (21.721–45.133) 29.566 (19.085–45.802)
HADS-A ≥8b
No 949 (9.20) 9 368 (90.80) 1.000 ref 1.000 ref
Yes 128 (13.43) 825 (86.57) 1.532 (1.257–1.867) 1.583 (1.225–2.044)
HADS-D ≥8b
No 1 040 (9.49) 9 915 (90.51) 1.000 ref 1.000 ref
Yes 183 (21.79) 657 (78.21) 2.655 (2.227–3.166) 1.429 (1.118–1.826)
Nagelkerke R2 0.319 0.296
−2 Log likelihood 6 593.252 5 200.042
HADS-A = self-reported questionnaire for symptoms of anxiety in which a score of ≥8 is consistent with clinically relevant symptoms of anxiety
HADS-D = self-reported questionnaire for symptoms of depression in which a score of ≥8 is consistent with clinically relevant symptoms of depression
aN in this analysis ranges from 13 135 to 11 113 and 12 551 to 10 961 for respectively women and men
bMissing data from several participants on this variable
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loss of hearing) of participants in HUNT2 with fibromyal-
gia versus the reference group. In addition, participants
with other, widespread and localized, musculoskeletal pain
were compared with the reference group. The reference
group was participants without musculoskeletal pain. Men
and women were analyzed separately. We adjusted for
previously known confounding factors for subjective loss
of hearing: measured loss of hearing (thresholds),
socio-demographic factors (age and education), and
psychological distress (clinical symptoms of depression
and anxiety). Measured loss of hearing and age were
not linearly associated with the outcome in any of the
subgroups and was categorized. Two adjusted models
were presented for both comparisons. Model 1 adjusted
for age, education, and measured hearing thresholds.
Model 2 was additionally adjusted for clinical symp-
toms of anxiety and depression.
Probability values less than 0.05 were considered sta-
tistically significant.
Results
Descriptive account of participants
The prevalence of fibromyalgia among participants
who answered these questions in HUNT 2 and
underwent audiometry testing was 3.3% (N = 1 483).
The prevalence for other musculoskeletal pain was for
local pain 19.7% (N = 8 749), for widespread pain
22.6% (N = 10 059), and for local and widespread pain
combined 42.3% (N = 18 808). Respondents who had
fibromyalgia or other musculoskeletal pain were more
often women, in a relationship, older, with lower levelof education, higher scores of anxiety and depressive
symptoms and higher average hearing thresholds than
the reference group without fibromyalgia and muscu-
loskeletal pain (Table 1).
Table 2 describes the two subgroups of persons with
local and widespread musculoskeletal pain other than
fibromyalgia. Persons with widespread pain were more
commonly women, in a relationship, older, with lower
level of education and higher scores of anxious and de-
pressive symptoms, compared to persons with local
musculoskeletal pain.
The relationship between fibromyalgia and subjective
hearing loss
Table 3 shows that persons with fibromyalgia had in-
creased probability of reporting subjective hearing loss,
compared to persons in the reference group. The OR
(95% CI) for subjective hearing loss was 5.182 (4.278–
6.277) for women and 4.368 (3.082–6.189) for men with
fibromyalgia, compared to women and men in the refer-
ence group after adjustment for age, education and mea-
sured hearing thresholds (WHO grade) (model 1). After
additional adjustment for clinically relevant anxious and
depressive symptoms (HADS-A ≥ 8 and HADS-D ≥ 8)
(model 2), the OR (95% CI) for subjective hearing loss
was 4.578 (3.622–5.787) for women and 4.523 (3.077–
6.647) for men with fibromyalgia.
The relationship between other musculoskeletal pain
than fibromyalgia and subjective hearing loss
Table 4 shows that non-fibromyalgic persons who had
local and widespread musculoskeletal pain had increased
Table 4 OR (95 % CI) for subjective hearing loss by musculoskeletal pain, socioeconomic conditions, measured hearing loss,
depression and anxiety in women and mena
Subjective hearing loss Unadjusted Adjusted for age,
education and





N (%) N (%) OR (95% CI) OR (95% CI) OR (95% CI)
WOMEN (21 808) 2 383 (10.93) 19 425 (89.07)
Musculoskeletal pain
None 805 (6.79) 11 055 (93.21) 1.000 ref 1.000 ref 1.000 ref
Local 558 (13.42) 3 600 (86.58) 2.129 (1.899–2.386) 1.901 (1.657–2.182) 1.915 (1.627–2.255)
Widespread 1 020 (17.62) 4 770 (82.38) 2.937 (2.661–3.240) 3.145 (2.788–3.548) 3.073 (2.668–3.539)
Age
20–35 156 (2.61) 5 829 (97.39) 1.000 ref 1.000 ref 1.000 ref
36–49 283 (4.22) 6 426 (95.78) 1.646 (1.349–2.007) 1.212 (0.987–1.490) 1.172 (0.940–1.460)
50–64 552 (11.21) 4 371 (88.79) 4.719 (3.934–5.661) 2.202 (1.800–2.693) 2.220 (1.785–2.762)
65+ 1 392 (33.21) 2 799 (66.79) 18.583 (15.654–22.059) 2.916 (2.357–3.608) 3.064 (2.415–3.887)
Education
Primary school 1 470 (19.31) 6 143 (80.69) 1.000 ref 1.000 ref 1.000 ref
High school 505 (5.68) 8 387 (94.32) 0.252 (0.226–0.280) 0.761 (0..665–0.870) 0.771 (0.661–0.899)
Higher 408 (7.69) 4 895 (92.31) 0.348 (0.310–0.391) 0.836 (0.726–0.964) 0.896 (0.756–1.061)
WHO hearing impairment
None (<26 dB) 835 (4.52) 17 619 (95.48) 1.000 ref 1.000 ref 1.000 ref
Mild (26–40 dB) 723 (33.32) 1 447 (66.68) 10.543 (9.419–11.805) 6.150 (5.367–7.047) 6.393 (5.445–7.506)
Moderate (41–60 dB) 644 (67.08) 316 (32.92) 43.002 (36.959–50.035) 25.229 (21.099–30.168) 25.202 (20.300–31.286)
Severe (>60 dB) 181 (80.80) 43 (19.20) 88.819 (63.239–124.745) 57.021 (39.859–81.574) 53.218 (34.360–82.427)
HADS-A ≥8b
No 1 365 (8.61) 14 493 (91.39) 1.000 ref 1.000 ref
Yes 405 (14.06) 2 476 (85.94) 1.737 (1.542–1.956) 1.703 (1.448–2.004)
HADS-D ≥8b
No 1 707 (9.21) 16 830 (90.79) 1.000 ref 1.000 ref
Yes 361 (20.74) 1 379 (79.25) 2.581 (2.275–2.928) 1.285 (1.063–1.552)
Nagelkerke R2 0.390 0.378
−2 Log likelihood 10 334.633 7 789.274
MEN (21 203) 3 576 (16.87) 17 627 (83.13)
Musculoskeletal pain
None 1 335 (10.82) 11 008 (89.18) 1.000 ref 1.000 ref 1.000 ref
Local 884 (19.26) 3 707 (80.74) 1.966 (1.792–2.158) 1.851 (1.662–2.061) 1.796 (1.590–2.029)
Widespread 1 357 (31.79) 2 912 (68.21) 3.843 (3.526–4.187) 3.739 (3.375–4.142) 3.618 (3.225–4.058)
Age
20–35 263 (5.07) 4 926 (94.93) 1.000 ref 1.000 ref 1.000 ref
36–49 489 (7.60) 5 946 (92.40) 1.540 (1.320–1.798) 1.124 (0.957–1.321) 1.064 (0.898–1.261)
50–64 1 076 (19.97) 4 311 (80.03) 4.675 (4.061–5.382) 1.978 (1.692–2.321) 1.934 (1.638–2.284)
65+ 1 758 (41.70) 2 444 (58.30) 13.396 (11.665–15.385) 2.375 (2.001–2.818) 2.152 (1.784–2.597)
Education
Primary school 1 658 (27.29) 4 418 (72.71) 1.000 ref 1.000 ref 1.000 ref
High school 1 313 (12.96) 8 822 (87.04) 0.397 (0.366–0.430) 0.892 (0.808–0.985) 0.884 (0.791–0.988)
Higher 605 (12.12) 4 387 (87.88) 0.367 (0.332–0.407) 0.757 (0.671–0.854) 0.688 (0.598–0.791)
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Table 4 OR (95 % CI) for subjective hearing loss by musculoskeletal pain, socioeconomic conditions, measured hearing loss,
depression and anxiety in women and mena (Continued)
WHO hearing impairment
None (<26 dB) 1 222 (7.50) 15 080 (92.50) 1.000 ref 1.000 ref 1.000 ref
Mild (26–40 dB) 1 135 (37.36) 1 903 (62.64) 7.360 (6.701–8.084) 4.775 (4.270–5.341) 4.842 (4.361–5.600)
Moderate (41–60 dB) 962 (62.63) 574 (37.37) 20.682 (18.368–23.288) 12.982 (11.221–15.020) 13.428 (11.428–16.060)
Severe (>60 dB) 257 (78.59) 70 (21.41) 45.307 (34.566–59.386) 31.241 (23.419–41.677) 29.054 (20.611–40.956)
HADS-A ≥8b
No 2 386 (14.25) 14 352 (85.75) 1.000 ref 1.000 ref
Yes 448 (21.13) 1 672 (78.87) 1.612 (1.440–1.804) 1.443 (1.242–1.676)
HADS-D ≥8b
No 2 577 (14.39) 1 533 (85.61) 1.000 ref 1.000 ref
Yes 585 (30.02) 1 364 (69.98) 2.552 (2.296–2.836) 1.555 (1.342–1.801)
Nagelkerke R2 0.361 0.348
−2 Log likelihood 14 108.014 11 358.869
HADS-A = self-reported questionnaire for symptoms of anxiety in which a score of ≥8 is consistent with clinically relevant symptoms of anxiety
HADS-D = self-reported questionnaire for symptoms of depression in which a score of ≥8 is consistent with clinically relevant symptoms of depression
aN in this analysis ranges from 21 808 to 18 210 and 21 203 to 18 355 for respectively women and men
bMissing data from several participants on this variable
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reference group. The probability was stronger in the
subgroup with widespread musculoskeletal pain, com-
pared to the subgroup with localized pain. The OR (95%
CI) for subjective hearing loss was 1.901 (1.657–2.182)
for women and 1.851 (1.662–2.061) for men with local
musculoskeletal pain, and 3.145 (2.788–3.548) for
women and 3.739 (3.375–4.142) for men with wide-
spread musculoskeletal pain, compared to the reference
group after adjustment for age, education and mea-
sured hearing thresholds (model 1). After additional
adjustment for clinically relevant anxious and depres-
sive symptoms (model 2), the OR (95% CI) for sub-
jective hearing loss was 1.915 (1.627–2.255) for
women and 1.796 (1.590–2.029) for men with local
musculoskeletal pain, and 3.073 (2.668–3.539) for
women and 3.618 (3.225–4.058) for men with wide-
spread musculoskeletal pain.
Discussion
In this population-based study, we found that both per-
sons who had been diagnosed with fibromyalgia and per-
sons with other musculoskeletal pain had increased
probability for subjective hearing, compared with a refer-
ence group without fibromyalgia or other musculoskel-
etal pain. The findings were adjusted for gender, age,
education, measured hearing impairment (audiometry,
WHO graded), clinical relevant symptoms indicating
anxiety and/or depression. Non-fibromyalgia respon-
dents with widespread musculoskeletal pain had signifi-
cantly higher odds to report subjective hearing loss than
persons with only localized pain.Main findings in light of theories about central nervous
sensitization
The previously mentioned theories about sustained
arousal, CATS and allostatic overload all conceptualize
how prolonged stress, probably in association with a
genetic predisposition [44], lead to sensitization of the
central nervous system, thereby enhancing the sensi-
tivity to stimuli, by some researchers termed central
sensitization syndrome (CSS) [24, 25]. This indicates
that both fibromyalgia and other musculoskeletal pain
might to a certain extent be explained by altered cen-
tral pain processing. Central mechanisms might ex-
plain both subjective alterations in the experience of
auditory stimuli and cognitive dysfunction [17]. In fu-
ture studies, it would be interesting to address auditory
perception among patients with fibromyalgia and other
chronic pain in a prospective and nuanced manner,
encompassing both experiences of explicit hearing
problems and hypersensitivity to sound.Comparisons with previous studies
To our knowledge, our study is the first to report a rela-
tionship between subjective hearing loss and fibromyal-
gia, as well as for other musculoskeletal pain in a
general population. The findings are in line with the pre-
viously mentioned clinical study by Wolfe et al. [28],
which however did not adjust for audiometrically mea-
sured hearing loss. Hashimoto et al. [30] who revealed
similar findings for conditions with three or more med-
ical unexplained symptoms did not include fibromyalgia
or other musculoskeletal pain disorders, nor did they
Stranden et al. BMC Musculoskeletal Disorders  (2016) 17:477 Page 9 of 10adjust for depression and anxiety symptoms, but ad-
justed for measured hearing loss.
Strengths and limitations
This study has several strengths. Firstly, despite the large
sample size (over 40 000 participants) and the self-
report approach used in the study, all participants were
assessed with audiometry in both ears with a validated
procedure. Thus, it was possible to adjust the analysis
of subjective hearing loss with objectively measured
hearing thresholds. Furthermore, the large sample size
gave power to run subgroup analyses and adjust for a
number of conditions known to affect subjective health
and hearing [28, 45, 46].
Moreover, it is a strength that fibromyalgia and other
musculoskeletal pain were studied separately in this
study. This is because the new diagnostic criteria for
fibromyalgia include more than just widespread muscu-
loskeletal pain [18, 19]. They also include cognitive dys-
function/problems, as stated in the introduction [17, 19].
Questions concerning musculoskeletal pain have been
validated through several studies [33, 34] where they
compared the answers on the questionnaires against the
diagnoses cervical spondylosis, adhesive capsulitis, lat-
eral epicondylitis, carpal tunnel syndrome and Raynaud’s
phenomenon [33]. Thus, the pain questions and pain
map used in HUNT 2, i.e. the Nordic pain questionnaire
(NPQ), appear relevant and valid [34].
The study also has some limitations. Firstly, the partic-
ipants were not diagnosed by physicians in the study set-
ting. The fibromyalgia diagnosis thus relied on the
participant’s response to whether a physician prior in
time had said the person had fibromyalgia. Thus, we do
not know if the persons responding “yes” to fibromyalgia
was evaluated using the formal diagnostic criteria. The
HUNT study was conducted in 1995–1997 when the
1990 diagnostic criteria for fibromyalgia were in force,
thus 2010 criteria were not used. Furthermore, we can-
not rule out the possibility that participants who re-
ported widespread pain had undiagnosed fibromyalgia.
In addition, we cannot exclude that wording in the ques-
tions concerning reported subjective hearing loss influ-
enced the responses. Furthermore, since this is a
retrospective cross-sectional study, conclusions concern-
ing causality cannot be drawn from the results.
Conclusions
Our study showed increased probability for subjective
hearing loss, both in persons with fibromyalgia and
other musculoskeletal pain, especially widespread pain,
after adjustment of audiometric measured hearing loss
and sociodemographic and psychological variables. The
finding supports the increasing recognition that medic-
ally unexplained pain conditions may pertain to a largerspectrum of symptoms, and that a common denomin-
ator for the different symptoms might be a more general
dysregulation in perception of sensory stimuli.
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